On ECHEMI
Home > Drugs > Exfoliation syndrome
Exfoliation syndrome
Exfoliation syndrome (pseudoexfoliation) is an abnormal protein in multiple ocular tissues, which blocks the trabecular meshwork, causing trabecular dysfunction, increased intraocular pressure and glaucoma. Exfoliation material appears as gray or bluish-white amorphous protein debris, which is not limited to the anterior lens capsule, but can also be seen on other ocular tissues with basement membranes, such as the suspensory ligament, cornea, iris, ciliary body, anterior vitreous surface and certain tissues outside the eyeball, such as conjunctival blood vessels and orbital tissue near the posterior pole of the eyeball, so it can also be called basement membrane syndrome. The trabecular meshwork often has obvious pigmentation, which can sometimes extend to Schwalbe's line. The glaucoma associated with it responds less to drug treatment than primary open-angle glaucoma. In 1917, Lindberg first described the deposition of debris at the pupil edge of these chronic glaucoma cases and revealed that this deposit was partly derived from the exfoliated anterior lens capsule. Histochemistry has proved that the debris of the anterior lens capsule is different from the lens capsule, and the lesion does not involve the lens capsule. Therefore, pseudoexfoliation was proposed to distinguish it from true exfoliation of the lens capsule in glassblowers under high temperature. Therefore, the name "exfoliation syndrome" is more appropriate.
  • Site of disease:

    Eye
  • Infectious :

    Not contagious
  • Frequent population:

    All groups
  • Related symptoms:

    Trabecular meshwork pigmentation Increased intraocular pressure Increased intraocular pressure Trabecular meshwork pigmentation
  • Concurrent disease:

Related Drugs
Riboflavin Sodium Phosphate for Injection
Indication: Riboflavin supplements. Used to treat angular cheilitis, cheilitis, glossitis, conjunctivitis, scrotitis and other diseases caused by riboflavin deficiency.
Manufacturer:

Hainan Tongyong Kangli Pharmaceutical Co., Ltd.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.